These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR). Herold TR; Rist K; Priglinger SG; Ulbig MW; Wolf A Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):221-229. PubMed ID: 27475933 [TBL] [Abstract][Full Text] [Related]
25. Eplerenone for treatment of chronic central serous chorioretinopathy. Fraenkel D; Suffo S; Langenbucher A; Seitz B; Abdin AD Eur J Ophthalmol; 2021 Jul; 31(4):1885-1891. PubMed ID: 32854564 [TBL] [Abstract][Full Text] [Related]
26. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624 [TBL] [Abstract][Full Text] [Related]
27. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202 [TBL] [Abstract][Full Text] [Related]
28. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lotery A; Sivaprasad S; O'Connell A; Harris RA; Culliford L; Ellis L; Cree A; Madhusudhan S; Behar-Cohen F; Chakravarthy U; Peto T; Rogers CA; Reeves BC; Lancet; 2020 Jan; 395(10220):294-303. PubMed ID: 31982075 [TBL] [Abstract][Full Text] [Related]
29. One year outcome and predictors of treatment outcome in central serous chorioretinopathy: Multimodal imaging based analysis. Arora S; Maltsev DS; Singh Randhir S; Sahoo NK; Jhingan M; Parmeshwarappa D; Arora T; Kulikov A; Iovino C; Zur D; Fainberg G; Ibrahim MN; Tatti F; Gujar R; Venkatesh R; Reddy N; Snehith R; Peiretti E; Lupidi M; Chhablani J Eur J Ophthalmol; 2022 Jul; 32(4):2319-2327. PubMed ID: 34747194 [TBL] [Abstract][Full Text] [Related]
30. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183 [TBL] [Abstract][Full Text] [Related]
31. Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy. Fasler K; Gunzinger JM; Barthelmes D; Zweifel SA Front Pharmacol; 2021; 12():675295. PubMed ID: 34040534 [No Abstract] [Full Text] [Related]
32. Central Serous Chorioretinopathy: Morphological and Functional Outcome after Subthreshold Thermal Laser Coagulation with a Frequency-Doubled Nd:YAG Continuous-Wave Laser. Enders C; Lang GE; Mayer B; Werner JU Ophthalmologica; 2022; 245(1):59-68. PubMed ID: 34517369 [TBL] [Abstract][Full Text] [Related]
33. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea. van Dijk EHC; Dijkman G; Boon CJF Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835 [TBL] [Abstract][Full Text] [Related]
34. Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serous Chorioretinopathy. Wuarin R; Kakkassery V; Consigli A; Roquelaure D; Papanastasiou A; Schutz JS; Thumann G; Chronopoulos A Optom Vis Sci; 2019 Jul; 96(7):500-506. PubMed ID: 31274738 [TBL] [Abstract][Full Text] [Related]
35. Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy. Park YJ; Kim YK; Park KH; Woo SJ Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):760-770. PubMed ID: 31877221 [TBL] [Abstract][Full Text] [Related]
36. Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy. Yavuz S; Balsak S; Karahan M; Dursun B J Fr Ophtalmol; 2021 Jan; 44(1):13-23. PubMed ID: 33279285 [TBL] [Abstract][Full Text] [Related]
37. Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy. Rabiolo A; Zucchiatti I; Marchese A; Baldin G; Sacconi R; Montorio D; Cicinelli MV; Querques L; Bandello F; Querques G; Eye (Lond); 2018 Jan; 32(1):55-66. PubMed ID: 29265111 [TBL] [Abstract][Full Text] [Related]
38. Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy. Daruich A; Matet A; Dirani A; Gallice M; Nicholson L; Sivaprasad S; Behar-Cohen F Transl Vis Sci Technol; 2016 Mar; 5(2):2. PubMed ID: 26966638 [TBL] [Abstract][Full Text] [Related]